Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. Methods: This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Results: Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42)for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. Conclusions: The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR. (Clin Mol Hepatol 2012;18:360-367)
Abstract
Background/Aims: Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients. Methods: This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860. Results: Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42)for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR. Conclusions: The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR. (Clin Mol Hepatol 2012;18:360-367)
참고문헌 (26)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
- Shin HR, "Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture", Br J Cancer, 87, pp.314~318 (2002)
- Wasley A, "Epidemiology of hepatitis C: geographic differences and temporal trends", Semin Liver Dis, 20, pp.1~16 (2000)
- Armstrong GL, "The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States", Hepatology, 31, pp.777~782 (2000)
- Di Bisceglie AM, "Natural history of hepatitis C: its impact on clinical management", Hepatology, 31, pp.1014~1018 (2000)
- Barrera JM, "Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C", Hepatology, 21, pp.639~644 (1995)
- Kim YS, "Prevalence of hepatitis C virus antibody among Korean adults", J Korean Med Sci, 7, pp.333~336 (1992)
- Strader DB, "The natural history of chronic hepatitis C infection", Eur J Gastroenterol Hepatol, 8, pp.324~328 (1996)
- YoungSunKim, "The Prognosis of Liver Cirrhosis in Recent Years in Korea", Journal of Korean Medical Science, 18(6), pp.833~841 (2003), 대한의학회
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C", Nat Genet, 41, pp.1105~1109 (2009)
- Suppiah V, "IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy", Nat Genet, 41, pp.1100~1104 (2009)
- Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- 강명주, "우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과", Clinical and Molecular Hepatology, 14(3), pp.318~330 (2008), 대한간학회
- Kim YJ, "The effectiveness of combination therapy with peginterferon alpha-2a and ribavirin in chronic Hepatitis C", Chonnam Med J, 44, pp.72~81 (2008)
- 김정일, "대전과 충청남북도에 거주하는 만성 C형간염 환자에서 페그인터페론 알파 2a와 2b의 초치료 효과 비교", Clinical and Molecular Hepatology, 14(4), pp.493~502 (2008), 대한간학회
- 이헌주, "한국인 만성 C형간염에서 페그인터페론 알파와 리바비린 또는 인터페론 알파와 리바비린의 병합요법: 치료기간에 따른 성적 비교", Clinical and Molecular Hepatology, 14(1), pp.46~57 (2008), 대한간학회
- Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin", JOURNAL OF CLINICAL VIROLOGY, 52(4), pp.363~366 (2011), Elsevier
- Sinn DH, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(9), pp.1374~1379 (2011), WILEY-BLACKWELL
- Dev AT, "Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome", Hepatology, 36, pp.1259~1265 (2002)
- Hepburn MJ, "Differences in treatment outcome for hepatitis C among ethnic groups", Am J Med, 117, pp.163~168 (2004)
- Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(Suppl 1), pp.S237~S244 (2002)
- 황상연, "만성 C형간염 환자에서 인터페론 알파와 리바비린 병합요법의 치료 효과와 합병증", 대한소화기학회지, 49(3), pp.166~172 (2007), 대한소화기학회